Biotech & Pharma
Health Tech
Business & Policy
Health & Science
Team
Exclusive analysis of biotech, pharma, and the life sciences
Topics
Columns
Tools
Events
Team
Account
More
Follow Us
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
In-depth analysis of biotech, pharma, and the life sciences
from some of the nation's most trusted and well-connected reporters in the industry
with STAT+ reporters and leading industry experts in our STAT+ Conversations series
hosted by STAT+, plus early-bird access and discounts to industry events around the country
get delivered to your inbox to brief you on the most important industry news of the day
like our CRISPR Trackr and Drug Pricing Policy Tracker
By Katie Palmer Sept. 14, 2022
A familiar refrain echoes through drug ads in the United States. It’s heard at the end of TV spots and plastered across magazine pages: Ask your doctor if this drug is right for you. But as medicine moves increasingly online, direct-to-consumer advertising is adopting a more assertive catchphrase: Talk to a doctor now.
Dozens of drug sites now have built-in buttons to “talk to a doctor now” about everything from novel migraine medications to a treatment for sickle cell disease. “You deserve to feel better,” reads one appeal about irritable bowel syndrome. Sponsored by AbbVie and Ironwood Pharmaceuticals, the manufacturers of IBS-C drug Linzess, the site invokes users to click to speak with a doctor in minutes, leading them to a third-party telehealth platform to “see if Linzess is right for you.”
Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!
Health Tech Correspondent
Katie is a health tech correspondent at STAT.
health tech
pharmaceuticals
STAT+
This name will appear with your comment
There was an error saving your display name. Please check and try again.
advertisement
Reporting from the frontiers of health and medicine
You’ve been selected! Subscribe to STAT+ for less than $2 per day
Unlimited access to essential biotech, medicine, and life sciences journalism
Subscribe to STAT+ for less than $2 per day
Unlimited access to the health care news and insights you need

source

Leave a Reply

Your email address will not be published.